Department of Internal Medicine
Hematology, Oncology and Blood & Marrow Transplantation Faculty
Guido Tricot, M.D.
Director, Bone Marrow Transplantation Program
Dr. Tricot's most recent clinical studies focus on not only attacking myeloma cells but also the microenvironment that supports the survival and growth of myeloma cells. His work aims at finding treatments that are non-cross-resistant with current chemotherapy and therefore can eradicate the drug-resistant myeloma cells. His work on detailed genetics of myeloma cells should allow individualized therapies to ensure the greatest efficacy, while minimizing toxicity. Over the last 15 years, the median survival for patients newly diagnosed with myeloma has, in large part due to this work, increased from 2.5 to more than 10 years. The complete remission rate has increased from 5% to 80% and one third of all patients are still in complete remission at 10 years.
Honors, Awards, and Organizations
- International Society of Hematology
- International Society for Experimental Hematology
- Dutch Society of Hematology
- American Society of Hematology
- Central Society for Clinical Research
- American Association for Cancer Research
- American Society for Blood and Marrow Transplantation
- Society for Biological Therapy
- American Medical Association
- Arkansas Medical Society
- Editor, Bone Marrow Research
- Editor, Leukemia
Links of Interest
- Zangari M, Tricot G, Polavaram L, Finlayson A, Knight R, Cavanaugh T, Fu T, Dimopoulos M, Niesvizky R, Fink L. (2009). Survival effect of venous thromboembolism (VTE) in multiple myeloma patients treated wtih Lenalidomide and high-dose Dexamethasone. J Clin Oncol. ;28:132-135.
- Fruehauf S, Tricot G. (2010) Comparison of Unmobilized and mobilized graft characteristics and the implications of celll subsets on autologous and allogeneic transplant outcomes. [Published online Feb 2010, in Press]
- Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu Chunjiao, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. (2010) Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1(1):22-33.
- Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD Jr, Nair B, Bellamy WT, Epstein J, Barlogie B, and van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012; 97:xxx doi:10.3324/haematol.2011.056747.